Trial Profile
Ticagrelor or Prasugrel Versus Clopidogrel in Elderly Patients With an Acute Coronary Syndrome and a High Bleeding Risk: Optimization of Antiplatelet Treatment in High-risk Elderly
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Clopidogrel (Primary) ; Prasugrel; Ticagrelor
- Indications Acute coronary syndromes; Myocardial infarction; Stroke; Unstable angina pectoris
- Focus Adverse reactions; Therapeutic Use
- Acronyms POPular-AGE
- 01 Jul 2021 Results of a pre-specified sub analysis (n=991) from the POPular Genetics and POPular Age trials assessing the effect of CYP2C19 loss-of-function alleles in clopidogrel treated elderly patients, published in the International Journal of Cardiology.
- 15 Sep 2020 Primary endpoint has been met. (Net clinical benefit at 1 year after randomisation)
- 15 Sep 2020 Results published in the Annals of Internal Medicine